Oncodesign Precision Medicine SA

XPAR:ALOPM (France)  
€ 1.44 (-2.71%) May 3
At Loss
Market Cap:
€ 26.07M ($ 28.08M)
Enterprise V:
€ 27.25M ($ 29.36M)
Volume:
9.17K
Avg Vol (2M):
8.08K
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Oncodesign Precision Medicine SA ( ) from 2022 to May 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Oncodesign Precision Medicine stock (XPAR:ALOPM) PE ratio as of May 04 2024 is 0. More Details

Oncodesign Precision Medicine SA (XPAR:ALOPM) PE Ratio (TTM) Chart

To

Oncodesign Precision Medicine SA (XPAR:ALOPM) PE Ratio (TTM) Historical Data

Total 401
  • 1
  • 2
  • 3
  • 4
  • 5
Oncodesign Precision Medicine PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-05 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss
2024-03-12 At Loss 2024-01-09 At Loss
2024-03-11 At Loss 2024-01-08 At Loss
2024-03-08 At Loss 2024-01-05 At Loss
2024-03-07 At Loss 2024-01-04 At Loss
2024-03-06 At Loss 2024-01-03 At Loss
2024-03-05 At Loss 2024-01-02 At Loss
2024-03-04 At Loss 2024-01-01 At Loss
2024-03-01 At Loss 2023-12-29 At Loss
2024-02-29 At Loss 2023-12-28 At Loss

Oncodesign Precision Medicine SA (XPAR:ALOPM) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Oncodesign Precision Medicine SA

ISIN : FR001400CM63
Compare
Compare
Traded in other countries / regions
ALOPM.FranceZR8.Germany
IPO Date
2022-10-05
Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.